In 2018, the FDA approved commercial sales of Tandem’s t:slim X2 insulin pump with Basal-IQ TechnologyTM — an insulin pump with Basal-IQ predictive low glucose suspend technology integrated with a continuous glucose monitor (CGM). The defining feature of this insulin pump is Basal-IQ technology. This smart technology helps users control glucose levels by predicting whether the user’s insulin levels are at risk of dropping below a predetermined number, and therefore at risk of hypoglycemia (low blood sugar), without a finger prick.
If you’re looking to start using an insulin pump, or if you’re ready to upgrade your current device, you might want to consider a touch screen insulin pump with Basal-IQ Technology.
How Basal-IQ Technology Predicts Lows
The Tandem t:slim X2 insulin pump with Basal-IQ Technology predicts lows by assessing trends in glucose readings from the CGM and automatically adjusting insulin delivery (it either releases insulin or withholds insulin delivery). The Basal-IQ technology analyzes glucose readings every five minutes to predict whether blood glucose levels will fall below a predefined glucose level within the next 30 minutes. In the case that blood glucose levels are consistently dropping, the pump will suspend subsequent insulin deliveries until readings begin to rise.
Clinically Shown to Reduce Hypoglycemic Events
A study published in October 2018 in Diabetes Care shows the efficacy and safety of the Tandem t:slim X2 insulin pump with Basal-IQ Technology. One hundred three individuals diagnosed with type 1 diabetes participated in this randomized, six-week study. During the study, the effectiveness of the Tandem t: slim X2 with Basal-IQ Technology, a Dexcom CGM, and a predictive low-glucose suspend algorithm (PLGS) was compared to sensor-augmented pump (SAP) therapy.
The results showed that using Basal-IQ Technology significantly reduced episodes of hypoglycemia (low blood sugar) compared to sensor-augmented therapy. Participants also experienced more time with blood sugar levels within a healthy range and did not experience an increase in hyperglycemia (high blood sugar).
These results suggest that the Tandem t:slim X2 insulin pump with Basal-IQ Technology can help children, adolescents, and adults manage glucose levels by helping to maintain blood glucose levels within a healthy range.
Helping Individuals with Diabetes Maintain Blood Glucose Levels Within Range
In addition to preventing hypoglycemic events, the Tandem t:slim X2 insulin pump with Basal-IQ Technology:
Is FDA approved for children as young as six years old
Provides automated insulin delivery
Integrates with the new Dexcom G6 Continuous Glucose Monitoring system to receive and display continuous glucose readings
Talk to Your Doctor About Basal-IQ Technology
If you’re interested in learning more about Basal-IQ Technology and how it might help you control blood glucose levels, talk to your doctor. Not everyone is a candidate for an insulin pump with Basal-IQ Technology: for example, individuals who have vision and/or hearing issues that do not allow them to recognize visual and auditory alerts.
Basal-IQ Technology is not a substitute for active diabetes care. Individuals interested in using a touchscreen insulin pump with Basal-IQ Technology should be willing to follow all diabetes care instructions as directed by their doctor.